许多种类的肿瘤可产生比普通细胞高得多的表皮生长因子受体，影响之一就是刺激了肿瘤细胞的扩散。
Many types of tumour produce far more EGFR than normal cells do, and one effect of that is to stimulate the proliferation of tumour cells.
例如，艾比特思和名为表皮生长因子受体(EGFR)的细胞表面蛋白的结合。
Erbitux, for example, binds to a cell-surface protein called epidermal growth-factor receptor (EGFR).
“从不吸烟的患者对一类叫表皮生长因子受体抑制剂的药物反应更好，因为这类患者有表皮生长因子受体基因突变的可能性更大一些。”鲁丁说。
"Patients who never smoked respond better to a certain class of drugs called EGFR inhibitors, because lung cancer in these patients more often contain mutations in the EGFR gene," Rudin says.
表皮生长因子受体通常促进细胞的生长发育，一旦发生基因变异，会使细胞不受控制地生长。细胞不受控制地生长，这正是癌症的特征。
EGFR normally promotes cell growth and development, and when mutated, allows the uncontrolled growth of cells that is the hallmark of cancer.
肺癌中表皮生长因子受体的突变及对靶向治疗的敏感性。
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
共有210名患有人表皮生长因子受体2 (HER2)阳性的早期乳腺癌的女性患者参加了实验。
A total of 210 women with early breast cancer who tested positive for human epidermal growth factor receptor 2 (HER2) were enrolled.
非小细胞肺癌病人的表皮生长因子受体基因突变的临床病理意义。
Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non-Small Cell Lung Cancer.
十多年前就取得了重大进展，一个加州的生物科技公司Genentech(中文名：基因泰克)发行了一种药物，这种药物攻击蛋白质HER2(中文名：人表皮生长因子受体- 2)含量过多的乳腺癌细胞。
A breakthrough came more than a decade ago when Genentech, a Californian biotech firm, launched a drug that attacks breast-cancer cells with too much of a certain protein, HER2.
肺癌中表皮生长因子受体基因的临床和生物学特点。
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers.
表皮生长因子受体(EGFR)在人类肝细胞广泛表达，表皮生长因子可能是肝细胞生长中必须的有丝分裂原。
Epidermal growth factor receptor (EGFR) is frequently expressed in human hepatoma cells, and EGF may be one of the mitogens that are needed for the growth of hepatoma cells.
目的研究抑制素、表皮生长因子受体在人卵巢颗粒细胞瘤中的表达及临床意义。
Objective To investigate the expression of inhibin, epidermal growth factor receptor in human ovarian granulosa cell tumor and their clinical significance.
结论：表皮生长因子受体抑制剂ag1487可对舌鳞癌细胞产生明显的增殖抑制作用。
Conclusion: Epidermal growth factor receptor inhibitor AG1487 may retard cell cycle, and then inhibit the proliferation of tumor cells.
目的：检测表皮生长因子受体(EGF - R)在舌癌患者常见舌苔中的表达水平，探讨EGF - R与舌苔形成的关系。
Objective: to investigate the relationship between the level of epidermal growth factor receptor (EGF-R) and tongue fur formation in tongue cancer patients.
目的：了解表皮生长因子受体抑制剂AG1487对舌鳞癌细胞的抑制增殖作用。
Objective:To investigate the inhibitory effect of epidermal growth factor receptor inhibitor AG1487 on the proliferation of tongue cancer cells.
目的探讨表皮生长因子受体与细胞增殖、转化的关系。
Objective to explore the relationship between epidermal growth factor receptor (EGFR) and cell proliferation and transformation.
2010年人表皮生长因子受体2检测：17号染色体着丝粒拷贝数是否具有影响？
Human Epidermal Growth Factor Receptor 2 Testing in 2010: Does Chromosome 17 Centromere Copy Number Make Any Difference?
目的：研究表皮生长因子受体和增殖细胞核抗原在胃肿瘤中的表达及其临床意义。
Objective: To study the expression of EGFR and PCNA protein in human gastric neoplasm and its clinical significance.
目的探讨表皮生长因子受体反义重组腺病毒联合放射线对乳腺癌细胞的作用。
Objective to investigate the effects of a recombinant antisense adenovirus for epidermal growth factor receptor combined with irradiation on breast cancer cells.
这是FDA批准的首个能够检测非小细胞肺癌患者表皮生长因子受体(EGFR)基因突变的、以血液为基础的基因检测试剂盒。
This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.
表皮生长因子受体(EGFR)通路下游基因的激活突变可以引起结直肠癌患者抗egfr耐药。
Activating mutations in downstream genes of the epidermal growth factor receptor (EGFR) pathway may cause anti-EGFR resistance in patients with colorectal cancers.
它的目标是一种蛋白质：驱动肿瘤生长的表皮生长因子受体(EGFR)。
It targets a protein - epidermal growth factor receptor (EGFR) - which drives tumour growth.
这种新药是用于治疗乳腺癌，这种携带了表皮生长因子受体2（Her-2）的特异生物标记的疾病。
The new drug is targeted to treat breast cancers that carry a special genetic marker, known as HER2.
目的探讨中国人非小细胞肺癌表皮生长因子受体(EGFR)第18、19、21外显子基因突变状态。
Objective to study the mutation patterns of epithelial growth factor receptor (EGFR) exon 18, 19 and 21 in Chinese non-small-cell lung cancers (NSCLC).
方法：我们随机分组表皮生长因子受体阳性、转移性、不可切除结直肠癌患者接受FOLFIRI单独化疗或联合西妥昔单抗化疗。
Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.
目的：研究表皮生长因子受体(EGFR)在口腔鳞癌组织中的表达及其临床病理学意义。
Purpose to study the expression and clinicopathological significance of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma (OSCC).
例如，委员会使用的关于单克隆抗体西妥昔单抗和帕尼单抗(它们抑制转移性结直肠癌的表皮生长因子受体egfr)的数据。
For example, the Panel used data for the monoclonal antibodies cetuximab and panitumumab, which inhibit the EGF receptor (EGFR) in metastatic colorectal cancer.
应用亲和毛细管电泳(ace)分析方法，对表皮生长因子受体(EGFR)和新多肽配体GE11之间的结合能力进行分析。
The binding ability of new peptide ligand GE11 and epidermal growth factor receptor (EGFR) was analyzed by affinity capillary electrophoresis (ACE) method.
应用亲和毛细管电泳(ace)分析方法，对表皮生长因子受体(EGFR)和新多肽配体GE11之间的结合能力进行分析。
The binding ability of new peptide ligand GE11 and epidermal growth factor receptor (EGFR) was analyzed by affinity capillary electrophoresis (ACE) method.
应用推荐